

Special Issue

The Applications of Radiomics in Precision Diagnosis and Treatment of Solid and Hematological Tumors

Message from the Guest Editors

Radiomics and artificial intelligence are largely expanded in health care systems, mainly in the oncological field and in the imaging setting. Their role as biomarkers for adding new information to the diagnosis of cancer and to monitor the response to therapy in solid and hematological disease is continuously increasing.

- To evaluate the role of radiomics and artificial intelligence in the diagnosis of solid and hematological cancers.
- To evaluate the role of radiomics and artificial intelligence in monitoring the response to therapy in solid and hematological cancers.

Guest Editors

Prof. Dr. Luigi Mansi

Section Health and Development, Interuniversity Research Center for Sustainability (CIRPS), 00038 Rome, Italy

Dr. Laura Evangelista

Department of Nuclear Medicine, Humanitas University, Pieve Emanuele, 20072 Milan, Italy

Deadline for manuscript submissions

closed (15 December 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



mdpi.com/si/152798

Cancers

MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)